参考文献/References:
[1] Buttgereit F,Bijlsma JWJ,Strehl C. Will we ever have better glucocorticoids?[J]. Clin Immunol,2018,186:64-66.
[2] Lattin CR,Kelly TR. Glucocorticoid negative feedback as a potential mediator of trade-offs between reproduction and survival[J]. Gen Comp Endocrinol,2019:113301.
[3] Vandermosten L,Vanhorebeek I,De Bosscher K,et al. Critical Roles of endogenous glucocorticoids for disease tolerance in malaria[J]. Trends Parasitol,2019,35(11):918-930.
[4] Fardet L,Feve B. Systemic glucocorticoid therapy:a review of its metabolic and cardiovascular adverse events[J]. Drugs,2014,74(15):1731-1745.
[5] Hadoke PW,Iqbal J,Walker BR. Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease[J]. Br J Pharmacol,2009,156(5):689-712.
[6] Meng H,Liu G,Zhai J,et al. Prednisone in uric acid lowering in symptomatic heart failure patients with hyperuricemia—The PUSH-PATH3 Study[J]. J Rheumatol,2015,42(5):866-869.
[7] Goodwin JE,Geller DS. Glucocorticoid-induced hypertension[J]. Pediatr Nephrol,2012,27(7):1059-1066.
[8] Hunter RW,Ivy JR,Bailey MA. Glucocorticoids and renal Na+ transport :implications for hypertension and salt sensitivity[J]. J Physiol,2014,592(8):1731-1744.
[9] Muller OG,Parnova RG,Centeno G,et al. Mineralocorticoid effects in the kidney:correlation between alphaENaC,GILZ,and Sgk-1 mRNA expression and urinary excretion of Na+ and K +[J]. J Am Soc Nephrol,2003,14(5):1107-1115.
[10] Funder JW,Pearce PT,Myles K,et al. Apparent mineralocorticoid excess,pseudohypoaldosteronism,and urinary electrolyte excretion:toward a redefinition of mineralocorticoid action[J]. FASEB J,1990,4(14):3234-3238.
[11] Goodwin JE,Zhang J,Velazquez H,et al. The glucocorticoid receptor in the distal nephron is not necessary for the development or maintenance of dexamethasone-induced hypertension[J]. Biochem Biophys Res Commun,2010,394(2):266-271.
[12] Kolluru GK,Bir SC,Kevil CG. Endothelial dysfunction and diabetes:effects on angiogenesis,vascular remodeling,and wound healing[J].Int J Vasc Med,2012,2012:918267.
[13] Williamson PM,Ong SL,Whitworth JA,et al. The role of sustained release isosorbide mononitrate on corticosteroid-induced hypertension in healthy human subjects[J]. J Hum Hypertens,2015,29(12):737-743.
[14] Fadel PJ. Nitric oxide and cardiovascular regulation:beyond the endothelium[J]. Hypertension,2017,69(5):778-779.
[15] Ong SL,Zhang Y,Sutton M,et al. Hemodynamics of dexamethasone-induced hypertension in the rat[J]. Hypertens Res,2009,32(10):889-894.
[16] Elena C,Chiara M,Angelica B,et al. Hyperglycemia and diabetes induced by glucocorticoids in nondiabetic and diabetic patients:revision of literature and personal considerations[J]. Curr Pharm Biotechnol,2018,19(15):1210-1220.
[17] Breakey S,Sharp SJ,Adler AI,et al. Glucocorticoid-induced hyperglycaemia in respiratory disease:a systematic review and meta-analysis[J]. Diabetes Obes Metab,2016,18(12):1274-1278.
[18] Chan HW,Cheung CY,Liu YL,et al. Prevalence of abnormal glucose metabolism in Chinese renal transplant recipients:a single centre study[J]. Nephrol Dial Transplant,2008,23(10):3337-3342.
[19] Radhakutty A,Mangelsdorf BL,Drake SM,et al. Effect of acute and chronic glucocorticoid therapy on insulin sensitivity and postprandial vascular function[J]. Clin Endocrinol (Oxf),2016,84(4):501-508.
[20] Croyle L,Morand EF. Optimizing the use of existing therapies in lupus[J]. Int J Rheum Dis ,2015,18(2):129-137.
[21] Wu GC,Liu HR,Leng RX,et al. Subclinical atherosclerosis in patients with systemic lupus erythematosus:a systemic review and meta-analysis[J]. Autoimmun Rev,2016,15(1):22-37.
[22] van Raalte DH,Diamant M,Ouwens DM,et al. Glucocorticoid treatment impairs microvascular function in healthy men in association with its adverse effects on glucose metabolism and blood pressure:a randomised controlled trial[J]. Diabetologia,2013,56(11):2383-91.
[23] Costenbader KH,Liang MH,Chibnik LB,et al. A pravastatin dose-escalation study in systemic lupus erythematosus[J]. Rheumatol Int,2007,27(11):1071-7.
[24] Alevizaki M,Cimponeriu A,Lekakis J,et al. High anticipatory stress plasma cortisol levels and sensitivity to glucocorticoids predict severity of coronary artery disease in subjects undergoing coronary angiography[J]. Metabolism,2007,56(2):222-6.
[25] Tanaka N,Masuoka S,Kusunoki N,et al. Serum resistin level and progression of atherosclerosis during glucocorticoid therapy for systemic autoimmune diseases[J]. Metabolites,2016,6(3):28.
[26] Miller LW. Cardiovascular toxicities of immunosuppressive agents[J]. Am J Transplant,2002,2(9):807-818.
[27] 耿明凤,马淑梅. 向心性肥胖与心血管疾病相关性的研究进展[J]. 心血管病学进展,2019,40(3):80-83.
[28] Valassi E,Santos A,Yaneva M,et al. The European Registry on Cushing’s syndrome:2-year experience.Baseline demographic and clinical characteristics[J]. Eur J Endocrinol,2011,165(3):383-392.
[29] Curtis JR,Westfall AO,Allison J,et al. Population‐based assessment of adverse events associated with long‐term glucocorticoid use[J]. Arthritis Rheum,2006,55(3):420-426.
[30] Da Silva JA,Jacobs JW,Kirwan JR,et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis:published evidence and prospective trial data[J]. Ann Rheum Dis,2006,65(3):285-293.
[31] Fardet L,Cabane J,Céleste Lebbé M,et al. Incidence and risk factors for corticosteroid-induced lipodystrophy:a prospective study[J]. J Am Acad Dermato, 2007,57(4):604-609.
相似文献/References:
[1]孙刚,黄冠华,综述.高血压合并心力衰竭的治疗策略[J].心血管病学进展,2016,(2):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
SUN Gang,HUANG Guanhua.Treatment Strategy of Hypertension with Heart Failure[J].Advances in Cardiovascular Diseases,2016,(4):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
[2]范贵娟,综述,徐瑞,等.盐敏感性高血压的研究进展[J].心血管病学进展,2016,(4):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
FAN Guijuan,XU Rui.Research Progress of Salt Sensitive Hypertension[J].Advances in Cardiovascular Diseases,2016,(4):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
[3]陈源源.钙通道阻滞剂在降压治疗中的应用[J].心血管病学进展,2015,(6):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
CHEN Yuanyuan.Application of Calcium Channel Blockers in Hypertension Treatment[J].Advances in Cardiovascular Diseases,2015,(4):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
[4]张瑞 毛露 孙硕 Dirk Hermann 陈艾东.内皮素-1干预成为高血压治疗新靶点的展望[J].心血管病学进展,2019,(7):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
ZHANG Rui MAO LuSUN ShuoDIRK Hermann CHEN Aidong.The Prospect of Endothelin-1 Intervention as A New Target for the Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2019,(4):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
[5]张毅,柳志红.动态血压监测在高血压中的应用现状与问题[J].心血管病学进展,2019,(6):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
ZHANG Yi,LIU Zhihong.Current status and nsolved Pproblems of Ambulatory Blood Pressure Monitoring for the Management of Hypertension[J].Advances in Cardiovascular Diseases,2019,(4):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
[6]黄秋瑾 胡蓉.高血压合并糖尿病患者血压控制率和控制目标的探讨[J].心血管病学进展,2019,(7):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
HUANG QiujinHU Rong.Discussion on Blood Pressure Control Rate and Control Target in Patients with Hypertension Complicated with Diabetes[J].Advances in Cardiovascular Diseases,2019,(4):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
[7]张旭明 王曦.高血压对认知功能的影响[J].心血管病学进展,2019,(7):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
ZHANG Xuming,WANG Xi.The Relationship Between Hypertension and Cognitive Function[J].Advances in Cardiovascular Diseases,2019,(4):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
[8]凌梦军 陈明凌梦军.阻塞性睡眠呼吸暂停低通气综合征与高血压关系的研究进展[J].心血管病学进展,2019,(5):722.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.015]
[9]李波 郭毅 田进文 邓珏琳.高血压合并2型糖尿病的治疗进展[J].心血管病学进展,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
LI Bo,GUO Yi,TIAN Jinwen,et al.Therapy in Hypertensive Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(4):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
[10]王继航 赵施皓 李开亮 田进文 李玉龙 付士辉 沈明志 邓珏琳.远程医疗在高血压病管理中的研究进展[J].心血管病学进展,2019,(9):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]
WANG Jihang,ZHAO Shihao,LI Kailiang,et al.Telemedicine in Hypertension Management[J].Advances in Cardiovascular Diseases,2019,(4):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]